Biocompatible and bioabsorbable derivatized chitosan compositions

US10709817B2 · kind B2 · utility

Assignee

• TRICOL BIOMEDICAL, INC. · US

Inventors

• Barbara McGrath · Portland, US
• Simon McCarthy · Portland, US
• Sam Kuhn · Portland, US
• Alysha Wold · Portland, US
• Michael Stolten · Portland, US
• Amanda Bennett · New Orleans, US

Key dates

• Filing date: Feb 13, 2018
• Grant date: Jul 14, 2020
• Expiry date: Feb 13, 2038

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2400/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to biocompatible, bioabsorbable derivatized non-crosslinked chitosan compositions optionally crosslinked to gelatin/collagen by 1-ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) for biomedical use and methods of making and testing such compositions, including a modified acute systemic toxicity test. The compositions comprise derivatized chitosan reacetylated to a degree of N-deacetylation (DDA) of between about 15% and 40%. The compositions are typically bioabsorbed in about 90 days or less and can be made to bioabsorb at differing rates of speed. The compositions are initially soluble in aqueous solution below pH 6.5. The compositions have an acid content that can be adjusted between about 0% (w/w) and about 8% (w/w) to customize the composition for uses that require and/or tolerate differing levels of cytotoxicity, adhesion, composition cohesion, and cell infiltration into the composition.